Evidence map›Paper›PMID 37471688›Full record

ArticleJournal of medicinal chemistry2023

C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein.

Marta Gargantilla, Clara Francés, Anmol Adhav, Alicia Forcada-Nadal, Belén Martínez-Gualda, Olaia Martí-Marí, María Luisa López-Redondo, Roberto Melero, Clara Marco-Marín, Nadine Gougeard and 12 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Marta GargantillaInstituto de Química Médica (IQM, CSIC), c/Juan de la Cierva 3, Madrid 28006, Spain.
Clara FrancésInstitute for Integrative Systems Biology (I2SysBio), UV-CSIC, c/Catedrático Agustin Escardino, 9, Paterna 46980, Valencia, Spain.ORCID 0000-0001-7341-3824
Anmol AdhavInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0002-3504-8675
Alicia Forcada-NadalInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0003-0179-4044
Belén Martínez-GualdaInstituto de Química Médica (IQM, CSIC), c/Juan de la Cierva 3, Madrid 28006, Spain.
Olaia Martí-MaríInstituto de Química Médica (IQM, CSIC), c/Juan de la Cierva 3, Madrid 28006, Spain.
María Luisa López-RedondoInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.
Roberto MeleroCentro Nacional de Biotecnología (CNB, CSIC), c/Darwin 3, Madrid 28049, Spain.
Clara Marco-MarínInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.
Nadine GougeardInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0001-7338-7267
Carolina EspinosaInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0009-0005-7504-3835
Antonio Rubio-Del-CampoInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0002-8482-2778
Rafael Ruiz-PartidaInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.
María Del Pilar Hernández-SierraInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0009-0004-5618-0159
Laura Villamayor-BelinchónInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.
Jerónimo BravoInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0001-6695-2846
José-Luis LlacerInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0001-5304-1795
Alberto MarinaInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.ORCID 0000-0002-1334-5273
Vicente RubioInstituto de Biomedicina de Valencia (IBV, CSIC), c/Jaime Roig 11, Valencia 46010, Spain.
Ana San-FélixInstituto de Química Médica (IQM, CSIC), c/Juan de la Cierva 3, Madrid 28006, Spain.ORCID 0000-0003-4271-7598
Ron GellerInstitute for Integrative Systems Biology (I2SysBio), UV-CSIC, c/Catedrático Agustin Escardino, 9, Paterna 46980, Valencia, Spain.
María-Jesús Pérez-PérezInstituto de Química Médica (IQM, CSIC), c/Juan de la Cierva 3, Madrid 28006, Spain.ORCID 0000-0003-1336-7760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, by infecting cells via the interaction of its spike protein (S) with the primary cell receptor angiotensin-converting enzyme (ACE2). To search for inhibitors of this key step in viral infection, we screened an in-house library of multivalent tryptophan derivatives. Using VSV-S pseudoparticles, we identified compound

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2Cryoelectron MicroscopyHumansProtein BindingSpike Glycoprotein, CoronavirusTryptophanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Tryptophan

Identifiers

PMID37471688
PMCPMC10424185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.